Page 1 of Clinical Trials for Abramson Cancer Center of the University of Pennsylvania [SPONSOR-COLLABORATORS], 92 Total Matches
- 1RecruitingLast Updated: May 17, 2012Condition(s): Advanced Myeloma.
- 2RecruitingLast Updated: January 25, 2012Condition(s): Systemic Myeloma; Multifocal Myeloma
- 3RecruitingLast Updated: June 8, 2011Condition(s): Patients With Renal Cell Carcinoma Who Are Newly Initiating Therapy; With the Oral Tyrosine-kinase Inhibitor Sunitinib.
- 4CompletedLast Updated: June 8, 2011Condition(s): Patients With Advanced Urothelial Carcinoma.
- 5RecruitingLast Updated: May 17, 2012Condition(s): Myeloma
- 6CompletedLast Updated: May 3, 2010Condition(s): Prostate Cancer
- 7CompletedLast Updated: May 17, 2012Condition(s): Male and Female Subjects, Greater Than 60 Years of Age With Non-M3 AML
- 8Active, not recruitingLast Updated: February 7, 2012Condition(s): Carcinoma, Renal Cell
- 9RecruitingLast Updated: May 17, 2012Condition(s): Adult Brain Tumor; Adult Brain Stem Glioma; Adult Diffuse Astrocytoma; Adult Ependymoma; Adult Grade II Meningioma; Adult Melanocytic Lesion; Adult Meningeal Hemangiopericytoma; Adult Mixed Glioma; Adult Oligodendroglioma; Adult Pineal Gland Astrocytoma; Adult Pineocytoma; Recurrent Adult Brain Tumor
- 10RecruitingLast Updated: March 6, 2012Condition(s): Prostate Cancer Patients With Detectable PSA Following Prostatectomy
- 11RecruitingLast Updated: May 17, 2012Condition(s): Hot Flashes
- 12CompletedLast Updated: April 13, 2011Condition(s): Breast Cancer
- 13RecruitingLast Updated: December 22, 2011Condition(s): Metastatic Melanoma
- 14TerminatedLast Updated: March 23, 2010Condition(s): Breast Cancer; Lymphedema
- 15RecruitingLast Updated: May 17, 2012Condition(s): Chemotherapy; Tumor; Ovarian Cancer
- 16Active, not recruitingLast Updated: May 8, 2012Condition(s): Estrogen-receptor Positive Invasive Metastatic Breast Cancer
- 17RecruitingLast Updated: November 9, 2010Condition(s): Lymphoma
- 18RecruitingLast Updated: May 17, 2012Condition(s): Mammography
- 19RecruitingLast Updated: January 11, 2012Condition(s): Histological Evidence of Metastatic Clear Cell Renal Cell Carcinoma; That Has Been Previously Treated With 1-3 Prior Regimens. Phase 1 Only, Any Number of Prior Regimens; With Evidence of Progressive Disease on or Within 6 Months; of Discontinuing Sunitinib, Sorafenib or Pazopanib. Previous; Therapy With Bevacizumab, IL2, or Interferon Are Permitted.
- 20RecruitingLast Updated: June 8, 2011Condition(s): Uterine Cancer; Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer; Cervical Cancer; Vulvar Cancer
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.
The URL of this page is: http://clinicaltrialsfeeds.org/clinical-trials/results/?spons=Abramson+Cancer+Center+of+the+University+of+Pennsylvania
